Nasdaq GlobeNewswire

Oxford Immunotec Reports Second Quarter 2017 Financial Results

  • Second quarter revenue of $26.1 million, an increase of 36% compared to prior year period
  • Continued growth from both the Tuberculosis and Tick-borne disease franchises
  • Successful negotiation of a settlement with Statens Serum Institut which will result in substantial future gross margin improvement
  • Raising revenue guidance for the full year from $102-$105 million to $103-$106 million

OXFORD, United Kingdom and MARLBOROUGH, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced second quarter 2017 financial results.

"We delivered a strong second quarter with revenue growth that exceeded the top end of our guidance range," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "As we continue our evolution from a single-product company to a multi-product company, we are pleased to see solid growth in our core tuberculosis (TB) business as well as a strong contribution from our accelerating tick-borne disease franchise."

By revenue type, total revenues were, in millions:

    Three Months Ended June 30,  
      2017     2016   Percent 

Product   $ 10.4   $ 9.3   12 %  
Service     15.7     9.9   59 %  
Total Revenue   $   26.1   $   19.2   36 %  

By indication, total revenues were, in millions:

    Three Months Ended June 30,  
      2017     2016   Percent 

Tuberculosis   $ 21.3   $ 19.2   12 %  
Tick-Borne Disease and Other     4.8     -   NM    
Total Revenue   $    26.1   $   19.2     36 %  

By geography, total revenues were, in millions:

    Three Months Ended June 30,  
            Percent Change  
      2017     2016   As Reported   Constant 
United States   $ 16.1   $ 9.8   65 %   65 %  
Europe & ROW     1.9     2.0   -2 %   3 %  
Asia     8.1     7.4   9 %   8 %  
Total revenue   $   26.1   $   19.2   36 %   36 %

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Settlement with Statens Serum Institut

During the quarter, we reached a settlement over a dispute regarding our license agreement with Statens Serum Institut (SSI). The terms of the settlement are confidential, however, we expect this settlement to result in a 300-400 basis point improvement in future TB gross margins.

Second Quarter 2017 Financial Results

Revenue for the second quarter of 2017 was $26.1 million, representing 36% growth over second quarter 2016 revenue of $19.2 million. On a constant currency basis, revenue growth was also 36% versus the prior year period. Tuberculosis revenue for the second quarter of $21.3 million increased 12% over the prior year period. 

2017 second quarter product revenue was $10.4 million, representing a 12% increase from product revenue of $9.3 million in the second quarter of 2016. The increase was primarily driven by sales of tick-borne disease kits as well as growth in Asia. Service revenue for the second quarter of 2017 was $15.7 million, up 59% from 2016 second quarter revenue of $9.9 million. The increase in service revenue was primarily driven by tuberculosis volume increases in the United States as well as revenues from our tick-borne disease testing business.

United States revenue was $16.1 million in the second quarter of 2017, representing 65% growth over revenue of $9.8 million in the prior year period. The increase was due to growth in our core tuberculosis business as well as the additional contribution from our tick-borne disease business.

Europe & ROW revenue was $1.9 million in the second quarter of 2017, representing a 2% decrease compared to the second quarter of 2016. On a constant currency basis, Europe & ROW increased 3% versus the second quarter of 2016. The increase was primarily due to TB growth, particularly in the UK, and sales of tick-borne disease kits.

Asia revenue was $8.1 million in the second quarter of 2017, representing an increase of 9% over 2016 second quarter revenue of $7.4 million. On a constant currency basis, Asia increased 8% versus the second quarter of 2016. The increase was due to the timing of orders in China and increasing sales in South Korea.

Gross profit for the second quarter of 2017 was $13.6 million, an increase of $3.1 million over gross profit of $10.5 million in the same period of 2016. Gross margin was 52.2%, a decrease of 290 basis points from the gross margin of 55.1% in the second quarter of 2016. The second quarter gross margin performance reflects an underlying improvement in TB margins offset by the addition of our tick-borne disease businesses, which carry lower gross margins.

Operating expenses were $31.4 million in the second quarter of 2017, an increase of $13.5 million compared to $17.9 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time charge related to the SSI settlement as well as expenses related to our BLA submissions and ongoing patent litigation.

Net loss for the second quarter of 2017 was $16.8 million, or $0.74 per share, compared to $6.4 million, or $0.29 per share, in the second quarter of 2016. Net loss per share was based on 22,805,379 and 22,351,645 weighted average ordinary shares outstanding for the second quarters of 2017 and 2016, respectively. 

EBITDA for the second quarter was $(17.4) million compared to $(5.8) million in the second quarter of 2016. Adjusted EBITDA was $(6.3) million for the second quarter compared to $(5.3) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

We expect to report revenue of between $29.5 and $30.5 million for the third quarter of 2017.

We now expect to report full year 2017 revenue of between $103 and $106 million, representing 20% - 23% year-over-year growth. We expect revenue to increase approximately 21% to 24% for the year using constant exchange rates. This compares to prior revenue guidance of between $102 and $105 million.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, August 1, 2017 at 8:00 a.m. Eastern Time to discuss its second quarter 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 54321779 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through the acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company's fourth intended product line focused on the transplantation market.  In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements

This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, the anticipated benefits of the transaction, the effects of the transaction, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: risks related to disruption of management time from ongoing business operations due to the integration of Imugen and Immunetics into the Company; the risk that the Company may fail to realize the benefits expected from the acquisitions; the risk that the integration of Imugen and Immunetics into the Company may not progress as anticipated; decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website,, or the SEC's website,

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.


For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377

Mark Klausner
Westwicke Partners
Tel: +1 (443) 213-0501

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
    Three months ended June 30,   Six months ended June 30,
(in thousands, except share and per share data)     2017       2016       2017       2016  
Product   $ 10,422     $ 9,293     $ 18,808     $ 17,431  
Service     15,698       9,861       28,817       18,833  
Total revenue     26,120       19,154       47,625       36,264  
Cost of revenue                
Product     4,094       3,512       7,339       6,805  
Service     8,398       5,094       15,650       9,966  
Total cost of revenue     12,492       8,606       22,989       16,771  
Gross profit     13,628       10,548       24,636       19,493  
Operating expenses:                
Research and development     3,948       3,284       7,753       6,305  
Sales and marketing     10,041       9,391       19,681       17,871  
General and administrative     7,990       5,151       14,866       9,734  
Change in fair value of contingent purchase price consideration     (238 )     57       (2,595 )     112  
Settlement expense     9,635       -       9,635       -  
Total operating expenses     31,376       17,883       49,340       34,022  
Loss from operations     (17,748 )     (7,335 )     (24,704 )     (14,529 )
Other income (expense):                
Interest expense, net     (807 )     (17 )     (1,630 )     (34 )
Foreign exchange (losses) gains     (547 )     874       (653 )     1,237  
Other (expense) income     (122 )     29       (262 )     (137 )
Loss before income taxes     (19,224 )     (6,449 )     (27,249 )     (13,463 )
Income tax benefit (expense)     2,458       3       2,411       (32 )
Net loss   $ (16,766 )   $ (6,446 )   $ (24,838 )   $ (13,495 )
Net loss per share attributable to ordinary shareholders-basic and diluted   $ (0.74 )   $ (0.29 )   $ (1.10 )   $ (0.60 )
Weighted-average shares used to compute net loss attributable to ordinary shareholders-basic and diluted     22,805,379       22,351,645       22,670,206       22,318,019  

Reconciliation of net loss to Adjusted EBITDA (1)
    Three months ended June 30,   Six months ended June 30,
(in thousands)     2017       2016       2017       2016  
Net loss   $ (16,766 )   $ (6,446 )   $ (24,838 )   $ (13,495 )
Income tax expense (benefit)     (2,458 )     (3 )     (2,411 )     32  
Interest expense, net     667       17       1,341       34  
Depreciation and amortization of intangible assets     990       624       1,993       1,205  
Accretion and amortization of loan fees     140       -       289       -  
EBITDA     (17,427 )     (5,808 )     (23,626 )     (12,224 )
Reconciling items:                
Share-based compensation expense     1,434       1,355       2,760       2,459  
Unrealized exchange losses (gains)     319       (896 )     281       (1,418 )
Change in fair value of contingent purchase price consideration     (238 )     57       (2,595 )     112  
Settlement expense     9,635       -       9,635       -  
Adjusted EBITDA   $ (6,277 )   $ (5,292 )   $ (13,545 )   $ (11,071

EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
    June 30,   December 31,
(in thousands, except share and per share data)     2017       2016  
Current assets:        
Cash and cash equivalents   $ 36,713     $ 59,110  
Accounts receivable, net     18,016       13,265  
Inventory, net     9,480       7,437  
Prepaid expenses and other assets     2,907       2,390  
Total current assets     67,116       82,202  
Restricted cash, non-current     200       200  
Property and equipment, net     8,786       7,793  
In-process research and development     16,170       16,170  
Goodwill     3,967       3,822  
Other intangible assets, net     10,410       11,017  
Deferred tax asset     6,133       2,630  
Other assets     145       178  
Total assets   $ 112,927     $ 124,012  
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $ 3,874     $ 3,201  
Accrued liabilities     15,734       14,282  
Settlement liability     2,317       -  
Contingent purchase price consideration     880       882  
Deferred income     43       41  
Current portion of loans payable     87       84  
Total current liabilities     22,935       18,490  
Long-term portion of loans payable     29,670       29,601  
Settlement liability     7,472       -  
Contingent purchase price consideration     -       2,593  
Other liabilities     364       364  
Total liabilities     60,441       51,048  
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at June 30, 2017 and 
December 31, 2016, and 23,014,032 and 22,635,431 shares issued and outstanding at June 
30, 2017 and December 31, 2016, respectively
    247       243  
Additional paid-in capital     251,989       249,128  
Accumulated deficit     (193,494 )     (168,656 )
Accumulated other comprehensive loss     (6,256 )     (7,751 )
Total shareholders' equity     52,486       72,964  
Total liabilities and shareholders' equity   $ 112,927     $ 124,012  

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

SEMAFO Mourns Passing of Board Chairman Jean Lamarre23.11.2017 22:01Pressemelding

MONTREAL, Nov. 23, 2017 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF) (OMX:SMF) announces with sadness the passing of Mr. Jean Lamarre, Chairman of the Board of Directors of the Corporation, on November 22, 2017 following a short illness. Mr. Lamarre joined the Corporation's Board of Directors in 1997 and was appointed Chairman of the Board in 2000, a position he held until his demise. "Jean made an indelible mark on SEMAFO, both in terms of his corporate governance expertise and his 45 years of experience in Africa," said President and CEO Benoit Desormeaux. "Over his 20-year tenure with SEMAFO, he brought unique insight, business acumen and leadership to the Corporation as it transitioned from an exploration company to a junior gold producer. He did this, always without compromising his values: the integrity of the Corporation, his deep love for Africa and its people, and his priority to SEMAFO's long-term sustainability. On behalf of SEMAFO's Board of Directors, management and employe

Premier to join industry leaders at BDA London forum23.11.2017 21:39Pressemelding

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- Premier David Burt will join more than two-dozen Bermuda executives in a multi-industry forum being held in London next week to showcase the breadth of expertise and advantages offered by the island's global business market. A photo accompanying this announcement is available at Organised by the Bermuda Business Development Agency (BDA), the one-day event Tuesday, November 28 at ME London has attracted over 200 registrants. It will feature top regulatory and industry leaders in moderated discussion panels covering re/insurance, captive insurance, insurance-linked securities, asset management, family offices, and trust and private-client business. A networking reception will wrap the event in the evening. "The government supports the Bermuda Business Development Agency in this awareness-raising event that offers such gre

Crown Bioscience and Data Sciences International (DSI) Partner to Advance Metabolic Disease Research Using an Implanted Telemetry Device for Long-Term Blood Glucose Monitoring23.11.2017 14:00Pressemelding

SANTA CLARA, Calif., Nov. 23, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation cardiovascular and metabolic disease research, announces the successful development of an enhanced method for preclinical obesity and type 2 diabetes studies in partnership with Data Sciences International (DSI). Crown Bioscience's clinically relevant models and DSI's HD-XG implantable glucose device combine to create a superior approach to preclinical metabolic disease research. Recently published work in the Journal of Endocrinological Investigation and Nature's Scientific Reports demonstrates the advantages of a new method using DSI's HD-XG implantable glucose device and Crown Bioscience's models of spontaneous and diet-induced diabetes. The HD-XG device allows for continuous, long-term measurement

Euroloan Opens New Market in Spain23.11.2017 11:10Pressemelding

Helsinki, Finland, 2017-11-23 11:10 CET (GLOBE NEWSWIRE) -- According to James Hickson, CEO of Euroloan Group, initiating services in the Spanish market is a key step in the expansion strategy of the Fintech group. “We have seen a growing demand for easy payment solutions in several markets, and the Spanish market in particular offers a massive opportunity for growth with Euroloan’s advanced payment and credit solutions. Merchants and Consumers appreciate our simple, fast and efficient services. It’s all about making their life easier. Consistent with our strategy, we have identified a number of partners to accelerate our market entry approach and expect to be providing our lending and merchant solutions by the end of the 1Q 2018” The Group is now present in five countries in Europe, including Finland, Sweden, Poland, Luxembourg and Spain. “Euroloan aims to open up several additional new markets”, says Tommi Lindfors, Chairman of the Board of Euroloan Group. “Spain is an importan

BDA partners with government to attract cryptocurrency23.11.2017 06:25Pressemelding

HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- The Bermuda Business Development Agency (BDA) will take a lead role in an initiative launched by the Bermuda government today to accelerate the establishment and growth of digital currency business on the island. A photo accompanying this announcement is available at At a press conference held by Premier the Hon David Burt and National Security Minister the Hon Wayne Caines, the government announced the formation of a task force comprising two teams to advance Bermuda's regulatory environment as a destination for utility tokens, tokenised securities, cryptocurrencies, and coin offerings. BDA Consultant for Emerging Technologies John Narraway was named as chair of the Blockchain Business Development Working Group, while BDA Board member Lydia Dickens will chair the Blockchain Legal and Regulatory Working Group, of which

VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39Pressemelding

The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes.  The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom